Matches in DBpedia 2016-04 for { ?s ?p "Jay Short is founder and CEO of the antibody drug company BioAtla, LLC [1]. Previously he was VP of R&D and Operations at Stratagene (now Agilent Technologies), then founder and CEO of Diversa until his departure in 2005. While at Diversa, Dr. Short invented methods of protein and pathway discovery via metagenomics, in addition to key evolution technologies Gene Site Saturation MutagenesisTM (GSSM) and GeneReassemblyTM, and was the first to combine these discovery and evolution technologies.On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's Conditionally Active Biologics (CAB) antibody platform and Pfizer's antibody drug conjugate (ADC) payloads. Both companies signed the deal in order to advance development and commercialization of a new class of antibody therapeutics. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.Dr. Short is also founder of the E. O. Wilson Biodiversity Foundation [2], Chairman of the Board of Ciris Energy [3], and member of the Board of Directors of Senomyx [4]. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Jay_Short abstract "Jay Short is founder and CEO of the antibody drug company BioAtla, LLC [1]. Previously he was VP of R&D and Operations at Stratagene (now Agilent Technologies), then founder and CEO of Diversa until his departure in 2005. While at Diversa, Dr. Short invented methods of protein and pathway discovery via metagenomics, in addition to key evolution technologies Gene Site Saturation MutagenesisTM (GSSM) and GeneReassemblyTM, and was the first to combine these discovery and evolution technologies.On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's Conditionally Active Biologics (CAB) antibody platform and Pfizer's antibody drug conjugate (ADC) payloads. Both companies signed the deal in order to advance development and commercialization of a new class of antibody therapeutics. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.Dr. Short is also founder of the E. O. Wilson Biodiversity Foundation [2], Chairman of the Board of Ciris Energy [3], and member of the Board of Directors of Senomyx [4]. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana.".
- Q6167185 abstract "Jay Short is founder and CEO of the antibody drug company BioAtla, LLC [1]. Previously he was VP of R&D and Operations at Stratagene (now Agilent Technologies), then founder and CEO of Diversa until his departure in 2005. While at Diversa, Dr. Short invented methods of protein and pathway discovery via metagenomics, in addition to key evolution technologies Gene Site Saturation MutagenesisTM (GSSM) and GeneReassemblyTM, and was the first to combine these discovery and evolution technologies.On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's Conditionally Active Biologics (CAB) antibody platform and Pfizer's antibody drug conjugate (ADC) payloads. Both companies signed the deal in order to advance development and commercialization of a new class of antibody therapeutics. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.Dr. Short is also founder of the E. O. Wilson Biodiversity Foundation [2], Chairman of the Board of Ciris Energy [3], and member of the Board of Directors of Senomyx [4]. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana.".